Show simple item record

dc.contributor.authorTyrrell, J
dc.contributor.authorPaterson, C
dc.contributor.authorCurnow, A
dc.date.accessioned2019-01-16T10:06:06Z
dc.date.issued2019-01-10
dc.description.abstractPhotodynamic therapy (PDT) is a light activated drug therapy that can be used to treat a number of dermatological cancers and precancers. Improvement of efficacy is required to widen its application. Clinical protoporphyrin IX (PpIX) fluorescence data were obtained using a pre-validated, non-invasive imaging system during routine methyl aminolevulinate (MAL)-PDT treatment of 172 patients with licensed dermatological indications (37.2% actinic keratosis, 27.3% superficial basal cell carcinoma and 35.5% Bowen's disease). Linear and logistic regressions were employed to model any relationships between variables that may have affected PpIX accumulation and/or PpIX photobleaching during irradiation and thus clinical outcome at three months. Patient age was found to be associated with lower PpIX accumulation/photobleaching, however only a reduction in PpIX photobleaching appeared to consistently adversely affect treatment efficacy. Clinical clearance was reduced in lesions located on the limbs, hands and feet with lower PpIX accumulation and subsequent photobleaching adversely affecting the outcome achieved. If air cooling pain relief was employed during light irradiation, PpIX photobleaching was lower and this resulted in an approximate three-fold reduction in the likelihood of achieving clinical clearance. PpIX photobleaching during the first treatment was concluded to be an excellent predictor of clinical outcome across all lesion types.en_GB
dc.description.sponsorshipDuchy Health Charity Ltd.en_GB
dc.description.sponsorshipKilling Cancer, UKen_GB
dc.identifier.citationVol. 11en_GB
dc.identifier.doi10.3390/cancers11010072
dc.identifier.othercancers11010072
dc.identifier.urihttp://hdl.handle.net/10871/35475
dc.language.isoenen_GB
dc.publisherMDPIen_GB
dc.relation.urlhttps://www.ncbi.nlm.nih.gov/pubmed/30634715en_GB
dc.relation.urlhttps://doi.org/10.24378/exe.1103en_GB
dc.rights© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)en_GB
dc.subjectAmeluz)en_GB
dc.subjectMetvix)en_GB
dc.subjectaminolevulinic acid (ALAen_GB
dc.subjectdermatologyen_GB
dc.subjectfluorescenceen_GB
dc.subjectimagingen_GB
dc.subjectmethyl aminolevulinate (MALen_GB
dc.subjectnon-melanoma skin cancer (NMSC)en_GB
dc.subjectphotobleachingen_GB
dc.subjectphotodynamic therapy (PDT)en_GB
dc.subjectprotoporphyrin IX (PpIX)en_GB
dc.titleRegression analysis of protoporphyrin IX measurements obtained during dermatological photodynamic therapy (article)en_GB
dc.typeArticleen_GB
dc.date.available2019-01-16T10:06:06Z
dc.identifier.issn2072-6694
exeter.place-of-publicationSwitzerlanden_GB
dc.descriptionThis is the final version. Available from MDPI via the DOI in this record.en_GB
dc.descriptionThe dataset associated with this article is located in ORE at: https://doi.org/10.24378/exe.1103en_GB
dc.identifier.journalCancers (Basel)en_GB
dc.rights.urihttp://www.rioxx.net/licenses/all-rights-reserveden_GB
dcterms.dateAccepted2019-01-07
rioxxterms.versionAMen_GB
rioxxterms.licenseref.startdate2019-01-10
rioxxterms.typeJournal Article/Reviewen_GB
refterms.dateFCD2019-01-15T16:23:32Z
refterms.versionFCDAM
refterms.dateFOA2019-01-16T10:06:11Z
refterms.panelAen_GB


Files in this item

This item appears in the following Collection(s)

Show simple item record